Home
Storia in 2 fonti
Blockbuster Drug Gets Breast Cancer Approvals in Curative Setting
New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment
- ·
pharmaceutical-technology.com
FDA approves Enhertu for two HER2-positive early breast cancer indications
The FDA has approved Daiichi Sankyo and AstraZeneca’s Enhertu for two new indications in HER2-positive early breast cancer.
- ·
medpagetoday.com
Blockbuster Drug Gets Breast Cancer Approvals in Curative Setting
New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment